Company: RGNT
Filing Date: 2025-01-27
Form Type: DRS/A
Source: 0001213900-25-006676
Chunk: 147

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-27
Form: DRS/A
Chunk 147
---
 documents (e.g., statement of claim) of CSL with translations in Hebrew, English or Arabic, as required
under the applicable German and international rules of proceeding. Consequently, based on advice of a German legal counsel, we are in
the opinion that the legal proceeding initiated by CSL suffered a fundamental and material procedural error and that no enforceable German
judgement could derive thereto. In 2024, we have initiated a proceeding in Germany to annul said German court’s purported ruling.

Other than the
proceeding mentioned above, we are not currently a party to any material legal proceedings. We may, however, in the ordinary course
of business face various claims brought by third parties and we may, from time to time, make claims or take legal actions to assert
our rights, including intellectual property rights as well as claims relating to employment matters and the safety or efficacy of
our products. Any of these claims could subject us to costly litigation and, while we generally believe that we have adequate
insurance to cover many different types of liabilities, our insurance carriers may deny coverage, may be inadequately capitalized to
pay on valid claims, or our policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to
happen, the payment of any such awards could have a material adverse effect on our operations, cash flows and financial position.
Additionally, any such claims, whether or not successful, could damage our reputation and business.

<div align='center'>89

MANAGEMENT</div>

Executive Officers and Directors

The following table sets forth
information regarding our executive officers and directors, including their ages as of the date of this prospectus:

| Name                    |     | Age |     | Position                |
| Dr. Ehud Geller         |     |  78 |     | Director, Chairman      |
| Mr. Jeff Dykan          |     |  65 |     | Director                |
| Mr. Keith Valentine     |     |  56 |     | Director(1)             |
| Dr. Eli Hazum           |     |  76 |     | Chief Executive Officer |
| Mr. Arie ‌ Gordashnikov |     |  41 |     | Chief Financial Officer |
| Efraim Cohen-Arazi      |     |  68 |     | Director Nominee(1)     |
| Mr. Pini Ben-Elazar     |     |  52 |     | Director Nominee(1)(2